<DOC>
	<DOCNO>NCT00373646</DOCNO>
	<brief_summary>The purpose study evaluate Thalidomide treatment disseminate MALT Lymphoma relapse follow helicobacter pylorus ( HP ) - eradication chemotherapy radiation .</brief_summary>
	<brief_title>Thalidomide Mucosa Associated Lymphoid Tissue ( MALT ) Lymphoma Patients</brief_title>
	<detailed_description>The objective study evaluate effectivity safety thalidomide patient disseminated MALT lymphoma relapse follow HP-eradication , chemotherapy radiation . It phase II prospective single arm study target sample size 16 patient . Thalidomide give orally initial dose 100 mg maximum duration 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients histologically confirm MALT lymphoma measurable disease ( Stage IIV ) With first great relapse HPeradication , radiation chemotherapy Age &gt; 18 Must able tolerate therapy adequate cardiac , renal hepatic function ECOG status _ &lt; 2 Must capable understand purpose study give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>MALT Lymphoma</keyword>
	<keyword>thalidomide</keyword>
	<keyword>disseminate MALT Lymphoma relapse follow HP-eradication</keyword>
	<keyword>chemotherapy radiation</keyword>
</DOC>